Skip to main content

Table 1 Baseline demographics of the subjects on the study

From: Evidence for harm reduction in COPD smokers who switch to electronic cigarettes

 

COPD Controls

COPD E-Cig users

Baseline P-value between groups

Agec

65.3 (±5.5)

66.9 (±6.7)

0.350

Sex

21 M, 3 F

20 M, 4 F

-

COPD GOLD stage

 Stage 1

3

2

-

 Stage 2

5

6

-

 Stage 3

11

10

-

 Stage 4

5

6

-

post-BD FEV1b (L)

1.47 (1.13, 1.72)

1.25 (0.94, 1.78)

0.298

post-BD FVCb (L)

2.39 (2.1, 2.64)

2.37 (2, 2.65)

0.902

%FEV1/FVCc

56.2 (±10.3)

59.4 (±8.4)

0.244

Pack years of smokingc

51.7 (±9.9)

52.4 (±10.7)

0.365

Cig/dayc

20.5 (±3.3)

21.8 (±4.4)

0.228

CAT scoreb

20.5 (17.8, 24.3)

21.5 (17.8, 25.3)

0.710

COPD Exacerbationsa, c

2.1 (±1.1)

2.3 (±1)

0.440

Co-morbidities

 Respiratory failure

5

6

 

 CHF

3

3

 

 CHD

2

3

 

 Hypertension

9

8

 

 Diabetes

4

5

 

 OSAS

6

3

 

 Chronic Kidney Failure

1

0

 

 Liver cirrhosis

1

0

 

 Lung cancer

0

1

 

 Pulmonary hypertension

0

1

 

 GERD

3

2

 

 Degenerative joint disease

2

4

 

 Osteoporosis

2

1

 

 Depression/Anxiety

2

4

 
  1. Abbreviations: COPD Chronic obstructive pulmonary disease, M male, F female, BD bronchodilator, L litre, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, Cig conventional cigarettes, CAT COPD assessment tool, CHF chronic heart failure, CHD coronary heart disease, OSAS obstructive sleep apnoea syndrome, GERD Gastroesophageal reflux disease
  2. a COPD exacerbations in past 12 months
  3. b Median (interquartile range); c Mean (± standard deviation)